FINWIRES · TerminalLIVE
FINWIRES

研究快讯:CFRA 将摩根士丹利股票评级从“买入”上调至“强力买入”

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们维持220美元的目标价,假设资本市场状况良好,并采用17.7倍的2026年预期市盈率(高于三年(18.0倍)和五年(15.8倍)的历史平均水平)。我们将2026年每股收益预期上调1.00美元至12.45美元,2027年每股收益预期上调0.60美元至12.85美元,分别基于775亿美元(此前预期为761亿美元)和800亿美元(维持不变)的项目收入预期。我们认为,交易和投资银行业务的交易活动将成为推动增长的主要催化剂。此外,高企的股票市场也将提振摩根士丹利的财富管理和投资管理业务的手续费收入和净利息收入。摩根士丹利确认,2026年投资银行咨询业务(包括股权/债券承销和并购交易)的市场环境将有所改善。我们看到,经营杠杆正在推动利润率的提升,而人工智能有望成为提高效率比率的潜在工具。市场风险包括资产价格高企、信贷利差收窄以及未来利率走势的不确定性。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF